Liu, J. F., Tolaney, S. M., Birrer, M., Fleming, G. F., Buss, M. K., Dahlberg, S. E., . . . Matulonis, U. A. (2013). A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Styl ChicagoLiu, Joyce F., et al. A Phase 1 Trial of the PARP Inhibitor Olaparib (AZD2281) in Combination With the Anti-angiogenic Cediranib (AZD2171) in Recurrent Epithelial Ovarian or Triple-negative Breast Cancer. 2013.
Citace podle MLALiu, Joyce F., et al. A Phase 1 Trial of the PARP Inhibitor Olaparib (AZD2281) in Combination With the Anti-angiogenic Cediranib (AZD2171) in Recurrent Epithelial Ovarian or Triple-negative Breast Cancer. 2013.